{"id":439737,"date":"2021-02-19T07:03:14","date_gmt":"2021-02-19T12:03:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=439737"},"modified":"2021-02-19T07:03:14","modified_gmt":"2021-02-19T12:03:14","slug":"cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/","title":{"rendered":"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results"},"content":{"rendered":"
\n

BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Standard Time on the same day.<\/p>\n

\n Conference call information:<\/strong>\n <\/p>\n

US\/Canada\u00a0call: (877) 493-9121 \/ international call: (973) 582-2750\u00a0<\/p>\n

US\/Canada\u00a0archive: (800) 585-8367 \/ international archive: (404) 537-3406\u00a0<\/p>\n

Code for live and archived conference call is 7389616. Webcast link.<\/a><\/p>\n

For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at\u00a0www.cyclacel.com<\/u><\/a>. The webcast will be archived for 90 days and the audio replay for 7 days.\u00a0<\/p>\n

\n About Cyclacel Pharmaceuticals, Inc.<\/strong>\n <\/p>\n

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2\/9 inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating CYC140, a PLK1 inhibitor, in advanced cancers. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com<\/a>.<\/a><\/p>\n

\n Forward-looking Statements<\/strong>\n <\/p>\n

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and\/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n
Company:<\/td>\nPaul McBarron, (908) 517-7330, pmcbarron@cyclacel.com<\/a><\/td>\n<\/tr>\n
Investor Relations:<\/td>\nRusso Partners LLC, Jason Assad, (678) 570-6791, jason.assad@russopartnersllc.com<\/a><\/td>\n<\/tr>\n<\/table>\n

\u00a9 Copyright 2021 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel\u00ae<\/sup> are trademarks of Cyclacel Pharmaceuticals, Inc.<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Standard Time on the same day. Conference call information: US\/Canada\u00a0call: (877) 493-9121 \/ international call: (973) 582-2750\u00a0 US\/Canada\u00a0archive: (800) 585-8367 \/ international archive: (404) 537-3406\u00a0 Code for live and archived conference call is 7389616. Webcast link. For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at\u00a0www.cyclacel.com. The webcast will be archived for 90 … <\/p>\n

Continue reading “Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-439737","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Standard Time on the same day. Conference call information: US\/Canada\u00a0call: (877) 493-9121 \/ international call: (973) 582-2750\u00a0 US\/Canada\u00a0archive: (800) 585-8367 \/ international archive: (404) 537-3406\u00a0 Code for live and archived conference call is 7389616. Webcast link. For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at\u00a0www.cyclacel.com. The webcast will be archived for 90 … Continue reading "Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T12:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results\",\"datePublished\":\"2021-02-19T12:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/\"},\"wordCount\":537,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/\",\"name\":\"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=\",\"datePublished\":\"2021-02-19T12:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk","og_description":"BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Standard Time on the same day. Conference call information: US\/Canada\u00a0call: (877) 493-9121 \/ international call: (973) 582-2750\u00a0 US\/Canada\u00a0archive: (800) 585-8367 \/ international archive: (404) 537-3406\u00a0 Code for live and archived conference call is 7389616. Webcast link. For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at\u00a0www.cyclacel.com. The webcast will be archived for 90 … Continue reading \"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-19T12:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results","datePublished":"2021-02-19T12:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/"},"wordCount":537,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/","name":"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=","datePublished":"2021-02-19T12:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1NjIwNiMzOTg1NTA4IzIwMDY3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclacel-pharmaceuticals-to-release-fourth-quarter-and-full-year-2020-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=439737"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/439737\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=439737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=439737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=439737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}